<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The goals of this retrospective study were to comprehensively evaluate the impact of hepatic lymph node (HLN) involvement on survival in patients with synchronous resectable or unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and to highlight how to deal with such cases in the light of recent advances in chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The impact of HLN involvement on survival, along with various clinical, pathological, and therapeutic factors, was retrospectively evaluated in 61 patients with synchronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (resectable, 26; unresectable, 35), undergoing resection of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and histopathological evaluation between July 2000 and April 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The proportion with HLN <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> was 11.5 % in resectable cases and 28.6 % in unresectable cases </plain></SENT>
<SENT sid="3" pm="."><plain>On multivariate analysis using the Cox proportional hazards model, HLN <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P &lt; 0.001), along with non-resection of hepatic lesions (P &lt; 0.001), larger <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumor</z:e> volume (P &lt; 0.001), non-use of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy (P &lt; 0.001), involvement of 4 or more regional lymph nodes (P &lt; 0.001), and excessive lymphatic invasion (P = 0.02), was identified as an independent risk factor for shorter survival </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSIONS: To establish a new therapeutic strategy for synchronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, the HLNs should be examined histologically in patients undergoing resection of their primary colon and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
</text></document>